Ken Griffin Summit Therapeutics Inc. Call Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$6.89 - $31.93 $1.27 Million - $5.86 Million	183,600 Added 127.68%	327,400 $7.17 Million
Q2 2024 Aug 14, 2024	BUY	$2.39 - $10.92 $287,756 - $1.31 Million	120,400 Added 514.53%	143,800 $1.12 Million
Q1 2024 May 15, 2024	BUY	$2.55 - $5.07 $19,380 - $38,532	7,600 Added 48.1%	23,400 $96,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.83 $26,386 - $44,714	15,800 New	15,800 $41,000
Q1 2023 May 15, 2023	SELL	$1.38 - $5.41 $93,702 - $367,339	-67,900 Reduced 87.5%	9,700 $16,000
Q4 2022 Feb 14, 2023	BUY	$0.68 - $5.31 $34,884 - $272,403	51,300 Added 195.06%	77,600 $329,000
Q3 2022 Nov 14, 2022	SELL	$0.89 - $1.63 $26,166 - $47,922	-29,400 Reduced 52.78%	26,300 $31,000

192

75.8M

2.01M

2.84M

Ticker SMMT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 201,215,008
Market Cap $3.6B
Description
Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.